prikaz prve stranice dokumenta Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies
  Download
PDF 1.35 MB
Scientific paper - Review paper
Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies
Journal of Cerebral Blood Flow & Metabolism, 42 (2022), 2; 219-236. https://doi.org/10.1177/0271678X211039997
Skukan, Laura; Brezak, Matea; Ister, Rok; Klimaschewski, Lars; Vojta, Aleksandar; Zoldoš, Vlatka; Gajović, Srećko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Skukan, L., Brezak, M., Ister, R., Klimaschewski, L., Vojta, A., Zoldoš, V. & Gajović, S. (2022). Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies. Journal of Cerebral Blood Flow & Metabolism, 42. (2), 219-236. doi: 10.1177/0271678X211039997

Skukan, Laura, et al. "Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies." Journal of Cerebral Blood Flow & Metabolism, vol. 42, no. 2, 2022, pp. 219-236. https://doi.org/10.1177/0271678X211039997

Skukan, Laura, Matea Brezak, Rok Ister, Lars Klimaschewski, Aleksandar Vojta, Vlatka Zoldoš and Srećko Gajović. "Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies." Journal of Cerebral Blood Flow & Metabolism 42, no. 2 (2022): 219-236. https://doi.org/10.1177/0271678X211039997

Skukan, L., et al. (2022) 'Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies', Journal of Cerebral Blood Flow & Metabolism, 42(2), pp. 219-236. doi: 10.1177/0271678X211039997

Skukan L, Brezak M, Ister R, Klimaschewski L, Vojta A, Zoldoš V, and sur.. Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies. Journal of Cerebral Blood Flow & Metabolism [Internet]. 2022 February [cited 2024 November 26];42(2):219-236. doi: 10.1177/0271678X211039997

L. Skukan, et al., "Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies", Journal of Cerebral Blood Flow & Metabolism, vol. 42, no. 2, pp. 219-236, February 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:642820. [Accessed: 26 November 2024]

Metadata
Title (english)Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies
AuthorLaura Skukan
AuthorMatea Brezak
AuthorRok Ister
AuthorLars Klimaschewski
AuthorAleksandar Vojta
AuthorVlatka Zoldoš
AuthorSrećko Gajović
Author's institutionUniversity of Zagreb
School of Medicine
(Croatian Institiute for Brain Research)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Histology and Embryology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Cytology, Histology and Embryology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Neuroscience
Abstract (english)
Due to the limited therapeutic options after ischemic stroke, gene therapy has emerged as a promising choice, especially with recent advances in viral vector delivery systems. Therefore, we aimed to provide the current state of the art of lentivirus (LV) and adeno-associated virus (AAV) mediated gene interventions in preclinical ischemic stroke models. A systematic analysis including qualitative and quantitative syntheses of studies published until December 2020 was performed. Most of the 87 selected publications used adult male rodents and the preferred stroke model was transient middle cerebral artery occlusion. LV and AAV vectors were equally used for transgene delivery, however loads of AAVs were higher than LVs. Serotypes having broad cell tropism, the use of constitutive promoters, and virus delivery before the stroke induction via stereotaxic injection in the cortex and striatum were preferred in the analyzed studies. The meta-analysis based on infarct volume as the primary outcome confirmed the efficacy of the preclinical interventions. The quality assessment exposed publication bias and setbacks in regard to risks of bias and study relevance. The translational potential could increase by using specific cell targeting, post-stroke interventions, non-invasive systematic delivery, and use of large animals.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Cerebral Blood Flow & Metabolism
Numberingvol. 42, no. 2, pp. 219-236
p-ISSN0271-678X
e-ISSN1559-7016
DOIhttps://doi.org/10.1177/0271678X211039997
URN:NBNurn:nbn:hr:105:642820
Publication2022-02
Document URLhttp://journals.sagepub.com/doi/10.1177/0271678X211039997
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2022-05-13 07:46:26